Alimera Sciences, Inc.

ANI Pharmaceuticals has completed the acquisition of Alimera Sciences, strengthening its Rare Disease segment and expanding its ophthalmology portfolio. The transaction is expected to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and be substantially accretive thereafter.

Related tickers: ALIM, ANIP.

ANI Pharmaceuticals and Alimera Sciences have announced the closing date of their previously announced merger for September 16, 2024. The merger is subject to certain risks and forward-looking statements.

Related tickers: ANIP, ALIM.